MedPath

Herbal Oil application in the prevention of Mosquito bite

Not Applicable
Not yet recruiting
Conditions
Prevention of Malaria Disease
Registration Number
CTRI/2018/11/016336
Lead Sponsor
Gods Own Store LLP
Brief Summary

Eligible households from the selected communities screened in baseline interview will be randomized into three groups to use either the test product BMB or the comparator, mosquito net or both (BMB and net) to repel mosquitoes in their daily lives. The baseline interview with individual household head will collect demographic data of the entire household, presently used mosquito repellent, presence of adequate number of undamaged mosquito nets etc. Households will also be asked questions pertaining their past medical history, especially occurrence of mosquito transmitted diseases such as malaria and dengue.

Subjects will be evaluated at the end of every three months (assessment surveys) for upto 6 months, Participants will be inquired about any changes in incidences of mosquito bites, as experienced, after application of test product. In case subjects report fever with chills a blood samples will be collected to test for malaria parasite during follow-up surveys to test for incidence of malaria. The primary outcome of the study is detection of malaria parasites (P. falciparum and/or P. vivax) through examination of microscopic blood slides collected from finger-pricks. Safety analyses will be done at each visit. Any allergy or other adverse reactions to the test product will also be recorded. Participants’ opinion about the aesthetic nature of the test product will also be noted in Diary card.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
600
Inclusion Criteria
  • 1.Communities consisting of multiple households, living in proximity of each other will be chosen.
  • 2.The communities should have similar environment and mosquito prevalence.
  • 3.The communities should be accessible for the survey.
  • 4.Participants should be willing to sign a written consent for participation in the study.
  • 5.Participants must be willing to commit to use of intervention and assessment visits for evaluation.
  • 6.Participants must be willing to refrain from using any other means for protection from mosquitoes, such as mosquito repellent devices, cream, sprays etc, from the outset of the study until final evaluation (if patient force to take above said medicine, subject will be dropped from the study).
  • 7.Participants must agree to maintain hygienic life style.
Exclusion Criteria
  • 1.Communities that are distant from each other or inaccessible.
  • 2.Communities with dissimilar living environments and mosquito prevalence.
  • 3.Children under the age of one year.
  • 4.Participants with history of malaria, dengue or chikangunya in past 6 months.
  • 5.Participants with evidence or history of significant systemic, immunological, gastro-enteric or gastrointestinal disorder (People with hypothyroidism who are on adequate and stable thyroid replacement will not be excluded).
  • 6.Any participant who is not able to give adequate informed consent.
  • 7.Patients reporting use of prescription or non-prescription drugs that has not been pre-approved by the study physician.
  • 8.Participant with known allergies to the main components of the test or comparator product.
  • 9.Participation in another clinical trial or taking an investigational product in the past three months.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.Decrease in incidence of mosquito bites, both inside and outside household andDay 0 | Day 90 | Day 180
. Criteria for efficacy are:Day 0 | Day 90 | Day 180
2.Decrease in incidences of malaria transmitted by mosquitoes.Day 0 | Day 90 | Day 180
Secondary Outcome Measures
NameTimeMethod
The secondary endpoints comprise of the safety analyses i.e. adverse event including SAEsDay 0

Trial Locations

Locations (1)

Prakhar Hospital Pvt Ltd

🇮🇳

Nagar, UTTAR PRADESH, India

Prakhar Hospital Pvt Ltd
🇮🇳Nagar, UTTAR PRADESH, India
Dr Jitendra Singh Kushwaha
Principal investigator
7906261455
drortho2711@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.